The next meeting of the National Drug Scheduling Advisory Committee (NDSAC) is scheduled for December 3-4, 2023. The primary purpose of the meeting is to consider the following matters:

• Request for Unscheduled status for brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older

• Request for Schedule III status for acetaminophen and ibuprofen, when sold in oral, fixed-dose combinations, in package sizes containing either more than 36,000 mg of acetaminophen or more than 18,000 mg of ibuprofen
  
  and
  
  Unscheduled status for acetaminophen and ibuprofen, when sold in oral, fixed-dose combinations, in package sizes containing 36,000 mg or less of acetaminophen and 18,000 mg or less of ibuprofen

Interested Party

Individuals, companies or organizations seeking Interested Party status for this agenda item are invited to complete the Interested Party Application Form and submit it to NAPRA as soon as possible. All applications for Interested Party status must be submitted in writing to the NDSAC Secretariat via email no later than 4:00 p.m. (ET) on Thursday, October 19, 2023.

Alternate method of participation

Individuals, companies or organizations who chose not to pursue Interested Party status or have been denied the status can provide comments, in writing, related to the agenda items outlined above. The comments must be received by the NDSAC Secretariat via email no later than 4:00 p.m. (ET) on Friday, November 24, 2023. Please note: only an acknowledgement of receipt for the comments received will be provided. All comments or information provided by this alternate method of participation shall be provided to NAPRA and any person, association or other entity that has obtained Interested Party status.

For more information, please contact the NDSAC Secretariat via email at ndsac@napra.ca.